Ellacor's expansion into body markets signals shift in fractional ablative adoption beyond face.
Cytrellis has launched its full-body skin resurfacing technology in Australia, extending Ellacor's fractional ablative footprint beyond facial applications. The move reflects growing practitioner demand for body resurfacing—chest, décolletage, hands, and arms—where ablative fractional CO₂ and erbium platforms have historically faced adoption friction due to downtime and healing complexity.
Ellacor's microablative approach and proprietary healing protocol position it as an alternative to traditional fractional lasers in markets where practitioners seek differentiation and patient tolerance for extended recovery. Australia's aesthetic market has shown strong uptake of advanced body treatments, making it a logical expansion hub before broader rollout.
Fractional ablative technology expands into full-body resurfacing markets.
For U.S. practices, this signals Cytrellis' confidence in body-market penetration and likely foreshadows domestic body-indication marketing. Practices considering Ellacor investment should track real-world body-treatment case data and patient satisfaction metrics as the technology scales beyond facial use.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
